TIL cell therapy in HIV positive patient with metastatic melanoma: case report - Takeaways - MDSpire

TIL cell therapy in HIV positive patient with metastatic melanoma: case report

  • By

  • Brian Whetsell

  • Juan Alban

  • Adam Y. Lin

  • Jeffrey D. Wayne

  • Sunandana Chandra

  • May 20, 2026

  • 0 min

Share

  • 1

    TIL therapy is a promising treatment for metastatic melanoma, especially for patients who have progressed on immune checkpoint inhibitors.

  • 2

    The case study presents the first known instance of a patient with well-controlled HIV receiving TIL therapy for immunotherapy-refractory melanoma.

  • 3

    The patient tolerated TIL therapy with manageable toxicities, including cytokine release syndrome and hypotension, demonstrating its feasibility.

  • 4

    Imaging at day 44 showed a partial response, indicating early efficacy, although disease progression was noted by day 86.

  • 5

    This case highlights the need for including people living with HIV in clinical trials to better understand the safety and efficacy of cellular therapies.

Original Source(s)

TIL cell therapy in HIV positive patient with metastatic melanoma: case report

  • by Brian Whetsell, Juan Alban, Adam Y. Lin, Jeffrey D. Wayne, Sunandana Chandra

  • May 20, 2026

Related Content

Microbial Profiles in the Gut and Their Association with Immunotherapy Efficacy in Non-Small Cell Lung Cancer and Melanoma: A Comprehensive Review and Meta-Analysis

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy